1. Home
  2. AVNT vs BBIO Comparison

AVNT vs BBIO Comparison

Compare AVNT & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Avient Corporation

AVNT

Avient Corporation

HOLD

Current Price

$31.79

Market Cap

2.9B

Sector

Industrials

ML Signal

HOLD

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

HOLD

Current Price

$75.82

Market Cap

14.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVNT
BBIO
Founded
1927
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
14.7B
IPO Year
1993
2019

Fundamental Metrics

Financial Performance
Metric
AVNT
BBIO
Price
$31.79
$75.82
Analyst Decision
Buy
Strong Buy
Analyst Count
6
21
Target Price
$45.67
$76.24
AVG Volume (30 Days)
762.5K
1.8M
Earning Date
02-12-2026
10-29-2025
Dividend Yield
3.40%
N/A
EPS Growth
N/A
N/A
EPS
1.23
N/A
Revenue
$3,246,100,000.00
$353,780,000.00
Revenue This Year
$2.24
$127.64
Revenue Next Year
$2.35
$78.38
P/E Ratio
$25.82
N/A
Revenue Growth
1.03
62.46
52 Week Low
$27.48
$27.23
52 Week High
$44.78
$78.44

Technical Indicators

Market Signals
Indicator
AVNT
BBIO
Relative Strength Index (RSI) 58.93 62.87
Support Level $31.02 $75.82
Resistance Level $31.60 $78.44
Average True Range (ATR) 0.70 2.20
MACD 0.12 -0.24
Stochastic Oscillator 92.00 68.91

Price Performance

Historical Comparison
AVNT
BBIO

About AVNT Avient Corporation

Avient Corp manufactures and sells various chemical and plastic-based products to designers and plastic processors. The firm operates in two segments: Color, Additives and Inks, and Specialty Engineered Materials. The company's product portfolio includes concentrated color and ink blends, plastic resins, and various specialized polymer materials used in industries such as food packaging, construction, transportation, cosmetics, and healthcare. The color, additives, & ink segment and the distribution segment together generate a vast majority of revenue. More than half of the total revenue is derived from the United States.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: